SCHEMBL14909701

SCHEMBL14909701

COc1cc(-c2cncc(Br)c2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 3/20 0.49
GABRB3 P28472 3/20 0.49
GABRA5 P31644 2/20 0.49
GABRA3 P34903 2/20 0.49
CYP2A6 P11509 2/20 0.46
CYP19A1 P11511 1/20 0.46
DYRK1A Q13627 1/20 0.45
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
ACVR2A P27037 2/20 0.41
TGFBR2 P37173 2/20 0.41
MAPT P10636 1/20 0.40
LOX P28300 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
AAK1 Q2M2I8 2/20 0.40
LRRK2 Q5S007 1/20 0.40
S1PR1 P21453 1/20 0.39
GABRA1 P14867 2/20 0.38
GAK O14976 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13743320 0.83 CYP2A6 (0.49) GABRG2GABRB3CYP2A6CYP19A1DYRK1A
SCHEMBL16116782 0.80 LOX (0.55) GABRG2GABRB3CYP19A1DYRK1AACVR2A
SCHEMBL30626327 0.80 LOX (0.55) GABRG2GABRB3CYP19A1DYRK1AACVR2A
SCHEMBL31334609 0.80 GABRG2 (0.64) GABRG2GABRB3GABRA5GABRA3CYP19A1
SCHEMBL29141734 0.77 DYRK1A (0.53) CYP19A1DYRK1AACVR2ATGFBR2MAPT
SCHEMBL30042187 0.77 CYP19A1 (0.66) CYP2A6CYP19A1DYRK1ACYP11B1CYP11B2
SCHEMBL23576478 0.75 GRM5 (0.38) LOXLOXL2
SCHEMBL320312 0.75 CYP2A6 (0.50) CYP2A6CYP19A1CYP11B1CYP11B2LOX
SCHEMBL22977699 0.74 CYP2A6 (0.46) CYP2A6CYP11B1CYP11B2
SCHEMBL21823646 0.73 PDGFRB (0.51) CYP2A6CYP19A1DYRK1ACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK GABRG2 2501/4885GABRB3 2743/4885GABRA5 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.